Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism

Archives of Internal Medicine

Volumn 159, Issue 5, 1999, Pages 457-460

  Kuijer, Philomeen M M ^a,b,c   Hutten, Barbara A ^b   Prins, Martin H ^b   Büller, Harry R ^a  

^a Ctr Haemostasis Atherosclerosis I   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; COUMARIN; REVIPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM;

EID: 0033535397     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.5.457     Document Type: Article

References (17)

1. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest. 1995; 108(suppl 4):231S-246S.
2. Fihn SD, McDonell M, Martin D, et al, for the Warfarin Optimized Outpatient Follow-up Study Group. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med. 1993;118:511-520.
3. Landefeld CS, Beylh RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med. 1993;95:315-328.
4. Levine MN, Raskob G, Landefeld SC, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest. 1995;108(suppl 4):276-289.
5. van der Meer FJM, Rosendaal FR, Vandenbroucke W, Briët E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med. 1993;153:1557-1562.
6. van der Meer FJM, Rosendaal FR, Vandenbroucke W, Briët E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost. 1996;76:12-16.
7. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423-428.
8. Gitter MJ, Jaeger TM, Petterson TM, Gersri BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70:725-733.
9. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.
10. Prins MH, ten Cate JW. Optimale behandeling met orale anticoagulantia. Ned Tijdschr Geneeskd. 1996;140:1059-1061.
11. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 1987;82:703-713.
12. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144-152.
13. Landeleld CS, McGuire E, Rosenblatt MW. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 1990;89:569-578.
14. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991;78:2337-2343.
15. Wester JPJ, de Valk HW, Nieuwenhuis HK, et al. Riskfactors for bleeding during treatment of acute venous thromboembolism. Thromb Haemost. 1996;76:682-688.
16. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657-662.
17. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.